Trimazosin

• UNSPSC Description:

  Trimazosin is an orally active, quinazoline derivative which is structurally related to prazosin. Trimazosin shows hypotensive effect by selectively block α1-adrenoceptors[1][2].

• Target Antigen:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/trimazosin.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N1CCN(CC1)C2=NC3=C(C=C(C(OC)=C3OC)OC)C(N)=N2)OCC(C)(C)O

• Molecular Weight:

  435.47

• References & Citations:

  [1]J Vincent, et al. The cardiovascular effects of trimazosin and prazosin in the rabbit. Clin Exp Pharmacol Physiol. 1986 Aug;13(8):593-608. |[2]H L Elliott, et al. Trimazosin in normotensive subjects. Clin Pharmacol Ther. 1984 Feb;35(2):156-60.|[3]J. P. Buyniski, et al. Effects of Tiodazosin, Prazosin, Trimazosin and Phentolamine on Blood Pressure, Heart Rate and on Pre- and Postsynaptic α-Adrenergic Receptors in the Rat. Clinical and Experimental Hypertension , 1980, Vol.2(6), p.1039-1066.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  35795-16-5